Program
ianalumab
Also written as “VAY736”, “Ianalumab” and “ianalumab s.c. q4w”.
In Novartis's pipeline, BAFF-R inhibitor, ADCC-mediated B-cell depletor
. Its studies are mostly in Purpura, Thrombocytopenic, Idiopathic · Lupus Erythematosus, Systemic · Sjogren's Syndrome · Lupus Nephritis · Arthritis, Rheumatoid, led by Novartis.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 3416 open or running | phase 3since Jul 12, 2017 | Aug 23, 2013 | Mar 26, 2027phase 3 · NCT05639114 |
- Named in Novartis’s own pipeline as
VAY736 (ianalumab)
, phase 4, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 18 studies since Aug 23, 2013.
- Nov 4, 20225 phase 3 studiesNCT05639114, NCT05624749, NCT05653349 and 2 more
- May 15, 2023Phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT05885555 · 41 enrolled · United States, Argentina, Australia and more
- Aug 3, 2023Phase 3 study in Sjogren's SyndromeNCT05985915 · 612 enrolled · United States, Argentina, Australia and more
- Oct 2, 2023Phase 3 study in Lupus Erythematosus, SystemicNCT06133972 · 550 planned · United States, Argentina, Australia and more
- Feb 28, 2024Phase 2 study in Lupus Erythematosus, SystemicNCT06293365 · 155 enrolled · United States, Argentina, Canada and more
- May 8, 2024Phase 1 study in Lupus Erythematosus, SystemicNCT06411639
- Jun 17, 2024Phase 2 study in Scleroderma, DiffuseNCT06470048 · 203 enrolled · United States, Argentina, Austria and more
- Nov 11, 2024Phase 3 study in Lupus NephritisNCT06711887 · 348 planned · United States, Brazil, China and more
- May 5, 2025Phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT07039422
- Feb 12, 2026Phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT07421167 · 164 planned · United States
- May 26, 2026Phase 3 study in FatigueNCT07621809 · 570 planned · United States, Australia, Austria and more
- Jun 15, 2026Phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT07660172 · 36 planned
- Oct 1, 2026Primary completion moved from 2030-04-08 to 2034-04-03Date moved laterphase 3 · +48 months · NCT06133972
- Oct 15, 2026Phase 2 study withdrawnStudy stoppedNCT07039422 · “The study was discontinued due to evolving scientific \& feasibility considerations that could adversely affect recruitment, thereby redu…”
Ahead
- Mar 26, 2027Primary completion: phase 3 study in Lupus Erythematosus, SystemicNCT05639114
- Apr 12, 2027Primary completion: phase 3 study in Lupus Erythematosus, SystemicNCT05624749
- Jul 30, 2027Primary completion: phase 2 study in Scleroderma, DiffuseNCT06470048
- Sep 21, 2027Primary completion: phase 3 study in Lupus NephritisNCT05126277
TargetBeta
“BAFF-R inhibitor, ADCC-mediated B-cell depletor”the company's pipeline, read by Claude · source
“A fully human combinatorial antibody library (HuCAL)-derived monoclonal antibody targeting the B-cell-activating factor receptor (BAFF-R), ”NCIt, by rule
“Tumor necrosis factor receptor superfamily member 13C binding agent”ChEMBL 37, by rule
Other programs on TNFRSF13C
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-BAFFR Monoclonal Antibody ESG206rule | shanghai-escugen-biotechnology-co-ltd | phase 2 | 5 |
| Anti-BAFF-R/Anti-CD3 Bispecific Antibody LY4152199rule | Eli Lilly | phase 1 | 1 |
Studies
All 34 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07660172Purpura, Thrombocytopenic, Idiopathic | 2 | Not yet recruiting | Apr 22, 2033 | 36 |
| NCT07621809Fatigue · United States, Australia, Austria and more | 3 | Recruiting | Aug 15, 2029 | 570 |
| NCT07421167Purpura, Thrombocytopenic, Idiopathic · United States | 2 | Recruiting | Jan 18, 2029 | 164 |
| NCT07039422Purpura, Thrombocytopenic, Idiopathic | 2 | Withdrawn | Aug 30, 2030 | 0 |
| NCT06711887Lupus Nephritis · United States, Brazil, China and more | 3 | Recruiting | Aug 1, 2035 | 348 |
| NCT06470048Scleroderma, Diffuse · United States, Argentina, Austria and more | 2 | Active, not recruiting | Jul 30, 2027 | 203 |
| NCT06411639Lupus Erythematosus, Systemic | 1 | Withdrawn | Dec 17, 2025 | 0 |
| NCT06293365Lupus Erythematosus, Systemic · United States, Argentina, Canada and more | 2 | Active, not recruiting | Feb 17, 2026 | 155 |
| NCT06133972Lupus Erythematosus, Systemic · United States, Argentina, Australia and more | 3 | Recruiting | Apr 3, 2034 | 550 |
| NCT05985915Sjogren's Syndrome · United States, Argentina, Australia and more | 3 | Active, not recruiting | Apr 22, 2033 | 612 |
| NCT05885555Purpura, Thrombocytopenic, Idiopathic · United States, Argentina, Australia and more | 2 | Active, not recruiting | Feb 5, 2025 | 41 |
| NCT05653349Purpura, Thrombocytopenic, Idiopathic · United States, Argentina, Australia and more | 3 | Active, not recruiting | Oct 29, 2026 | 226 |
| NCT05653219Purpura, Thrombocytopenic, Idiopathic · United States, Argentina, Austria and more | 3 | Active, not recruiting | Jun 19, 2025 | 152 |
| NCT05648968Warm Autoimmune Hemolytic Anemia (wAIHA) · United States, Argentina, Australia and more | 3 | Active, not recruiting | Feb 20, 2026 | 90 |
| NCT05624749Lupus Erythematosus, Systemic · United States, Argentina, Australia and more | 3 | Active, not recruiting | Apr 12, 2027 | 288 |
| NCT05639114Lupus Erythematosus, Systemic · United States, Argentina, Brazil and more | 3 | Active, not recruiting | Mar 26, 2027 | 436 |
| NCT05349214Sjogren's Syndrome · United States, Argentina, Australia and more | 3 | Active, not recruiting | May 13, 2025 | 506 |
| NCT05350072Sjogren's Syndrome · United States, Austria, Belgium and more | 3 | Completed | May 7, 2025 | 275 |
| NCT05124925Sjogren's Syndrome · France | 2 | Completed | Jun 26, 2024 | 21 |
| NCT05126277Lupus Nephritis · United States, Argentina, Brazil and more | 3 | Active, not recruiting | Sep 21, 2027 | 452 |
| NCT04903197Lymphoma, Non-Hodgkin · Australia, China, Germany and more | 1 | Terminated | Feb 24, 2025 | 18 |
| NCT03827798Hidradenitis Suppurativa · United States, Austria, Belgium and more | 2 | Completed | Dec 4, 2024 | 248 |
| NCT03656562Lupus Erythematosus, Systemic · Argentina, Australia, China and more | 2 | Completed | Jul 27, 2022 | 107 |
| NCT03574545Arthritis, Rheumatoid · Germany, Jordan | 1 | Completed | Jul 18, 2024 | 48 |
| NCT03400176Leukemia, Lymphocytic, Chronic, B-Cell · United States | 1 | Terminated | Sep 29, 2023 | 39 |
| NCT03287414Idiopathic Pulmonary Fibrosis · United States, Canada, Germany and more | 2 | Terminated | Nov 25, 2020 | 30 |
| NCT03217422Hepatitis, Autoimmune · United States, Argentina, Belgium and more | 3 | Completed | Dec 28, 2023 | 68 |
| NCT02962895Primary Sjogren Syndrome · United States, Argentina, Austria and more | 2 | Completed | Jun 30, 2020 | 190 |
| NCT02675803Arthritis, Rheumatoid · Germany | 1 | Completed | Jan 22, 2018 | 65 |
| NCT02495129Sjogren's Syndrome | 2 | Withdrawn | Sep 2017 | 0 |
| NCT02137889Recurrence · United States, Spain | 1 | Terminated | Nov 2012 | 3 |
| NCT02038049Multiple Sclerosis · United States, Czechia, Ukraine | 2 | Terminated | May 5, 2015 | 8 |
| NCT02149420Primary Sjögren's Syndrome · Germany | 2 | Completed | Feb 7, 2018 | 27 |
| NCT01930175Pemphigus · United States, Austria, Bulgaria and more | 2 | Terminated | Sep 25, 2019 | 13 |
How it is read
Names in the registry
- “VAY736”, 15 entries
- “Ianalumab”, 11 entries
- “ianalumab”, 4 entries
- “ianalumab s.c. q4w”, 1 entry
- “ianalumab s.c. q12w”, 1 entry
Conditions, from the studies’ own filings
- Purpura, Thrombocytopenic, Idiopathic, 6 studies
- Lupus Erythematosus, Systemic, 6 studies
- Sjogren's Syndrome, 6 studies
- Lupus Nephritis, 2 studies
- Arthritis, Rheumatoid, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.